Pharmacogenomic diversity in psychiatry: Challenges and Opportunities in Africa

Muktar B. Ahmed[1], Anwar Mulugeta[2,3], Niran Okewole[4], Scott Clark[1], Conrad O. Iyegbe[5], Azmeraw T. Amare[1]

[1]Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, SA, Australia

[2] Australian Centre for Precision Health, University of South Australia, Adelaide, SA, Australia

[3] UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia

[4] Neuropsychatric Hopsital Aro, Abeokuta, Nigeria

[5]Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, USA

Correspondence to: Azmeraw T. Amare,

Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000,
Australia
Tel: +61 8 83137438
E-Mail: azmeraw.amare@adelaide.edu.au

Word count

Abstract: 475

Main body: 7033

Number of tables: 1

Number of figures: 3

Ref: 136

Abstract

Background: Studies on the pharmacogenomic of psychiatric drugs have slowly identified genetic variations that influence drug metabolism and treatment outcomes, including response, remission, and side effects. However, most of these studies predominantly entered on populations of European descent. As a result, there remains a significant knowledge gap pertaining to the extent of pharmacogenomic diversity among African populations and this raises a major question about the validity of translating the current evidence to enable pharmacogenomic genetic testing (PGx) for this population. The objective of this review was to appraise previous pharmacogenomic studies conducted in the African population, with a focus on psychiatric medications.

Methods: A systematic search was conducted on PubMed, Scopus, and Web of Science to identify studies published in the English language from inception up to February 06, 2023. The primary outcomes were treatment response, remission, side effects, and drug metabolism in African patients with major psychiatric disorders, such as depression and schizophrenia. Conference papers, abstracts, or articles lacking full text were excluded. To ensure data accuracy, two reviewers independently performed data extraction using the PRISMA reporting guideline.

Results: The review included 42 pharmacogenetics and pharmacogenomics studies that explored the genetic profiles of African psychiatric patients who received pharmacological therapy. While we found a limited number of studies, they provided strong evidence of pharmacogenomic diversity in African populations, highlighting the importance of investigating the role of genetics in the treatment of psychiatric disorders in this population. The frequencies of cytochrome P450 (CYP450) gene genotypes show high variability. For instance, up to 28% of individuals of North Africans and Ethiopians are ultrarapid metabolizers to several medications, attributed to increased activity of the *CYP2D6* enzymes, in contrast to 10% prevalence among Caucasians and 1% within Hispanic, Chinese, and Japanese populations. Genotyping the *CYP1A2* gene and using therapeutic drug monitoring (TDM) improved the effectiveness and safety of Clozapine in Tunisian patients with schizophrenia. In Ethiopia, 5.2% of the subjects were found to be poor metabolizers of S-mephenytoin, with a frequency of the *CYP2C19*2* allele at 14% and the *CYP2C19*3* allele at 2%.Among South African patients with schizophrenia, two gene variants (rs13025959 in the *MYO7B* gene with the 'C' allele and rs10380 in the *MTRR* gene with the 'T' allele) were found to impact treatment response to ???.

Conclusion: The review has identified evidence of pharmacogenomic diversity in African populations and recommended expanding pharmacogenomic studies while introducing PGx in this population. For the few characterized genes, Africans exhibit qualitative and quantitative differences in the profile of pharmacogenetic variants when compared to other ethnic groups. Limited research funding, inadequate infrastructure, and a shortage of skilled human resources might be a challenge, but by building upon local successes and through collaborations with international partners, it is possible to leverage global genetic knowledge and sequencing technology for the development of personalized treatment approaches in Africa.

Keywords: Pharmacogenomics; Personalized medicine; Psychiatric disorders, Africa; Genetic variants, depression, schizophrenia

Introduction

Psychiatric disorders continue to be a major global concern, ranking among the top ten leading causes of disease burden worldwide (1). In 2019, mental disorders accounted for 125.3 million disability-adjusted life years (DALYs) globally, representing 4.9% of the global burden of disease (1). The prevalence of mental health disorders is a significant challenge in Africa, given the region's socioeconomic and political adversities (2). According to a scoping review of 36 studies from 12 African countries, lifetime prevalence rates of mood disorders range from 3.3% to 9.8%, anxiety disorders range from 5.7% to 15.8%, substance use disorders range from 3.0% to 13.3%, and psychotic disorders range from 1.0% to 4.4% (3).

In order to tackle the significant prevalence of mental health disorders, access to pharmacotherapy is widely promoted, and various initiatives have been implemented to enhance the availability of mental healthcare services and medications throughout Africa. However, studies suggest that around 30-35% of patients with mental illness who receive pharmacological therapy do not respond adequately to treatment, regardless of the medication chosen initially (4) partly explained by the influence of genetic factors to the effectiveness of pharmacological treatment. Genetic factors contribute to 30-40% of the interindividual variability in treatment response to mood stabilizers and antipsychotics(5)(6) and a recent study found that common genetic variants accounting for 1.15-9.48% of the variance in the plasma concentration of clozapine and its metabolites (7). Furthermore, treatment outcomes in patients with psychiatric disorders is influenced by a complex interplay between genetic and environmental factors which underscores the complex and polygenic nature of treatment outcome phenotypes. For example, dimensional personality traits (8), stressful life events reported during or immediately prior to treatment (9) predict poor treatment response in patients with psychiatric disorders. In the essence of genetic factors, research by Amare et al., showed that in patients with bipolar disorder (BD), a high polygenic loading for schizophrenia (SCZ) or major depressive disorder (MDD) was associated with poor response lithium treatment response (10-12). Similarly, in patients with MDD, the polygenic score (PGS) for neuroticism and openness personality were associated with SSRIs treatment remission (13). Incorporating clinical predictors in conjunction with PGSs has enhanced the ability to predict the response to lithium treatment in patients with BD (14-16).

Studies, largely conducted in developed countries have informed the advantages of integrating genetic profiling to assist clinicians in optimizing therapy (17-19) and highlight the need for personalized psychiatric treatment and medication selection that is tailored to an individual's specific genetic profile (20). As a result, pharmacogenomic testing (PGx) has become increasingly available and widely adopted in the healthcare settings of developed countries. However, the issue of pharmacogenomic diversity, especially when comparing African and European populations, poses challenges for the application of existing genetic tests to African populations (21)(22). Previous research has indicated that a significant number of medications have been developed and trialled on non-African populations, predominantly Caucasians and Asians (23-26). This means that African populations may not fully benefit from existing PGxs due to their underrepresentation in pharmacogenomic studies from which these tests were developed.(27, 28). To gain a more profound perspectives into the scope of psychiatric pharmacogenomics in African populations, we conducted a thorough and systematic review and assessed potential prospects and obstacles that could advance psychiatric PGx within the African populace. We also highlighted on how leveraging the global community could benefit from pharmacogenomics diversity of Africans.

Method

Search strategy

We conducted a comprehensive search of papers published from the inception of PubMed, SCOPUS, and Web of Science databases until 06/02/2023. The search strategy involved two sets of keywords - pharmacogenetics and pharmacogenomics and used database-specific search terms. For PubMed, we used Medical Subject Headings (MeSH) and text word search in our search methodology. For SCOPUS, we conducted a search using Emtree (EMBASE vocabulary) terms, as well as a text word search. We included the following keywords and their combinations in our search methodology: "pharmacogenomics", "pharmacogenetics", "psychiatric disorders", "Africa", and relevant MeSH terms. We extracted information on the relevant genes, outcome, the type of psychiatric disorders, and the specific population included in the analyses. To ensure a comprehensive search, the search terms were broadened by including synonymous and related terms for each of the keywords. For instance, we included terms such as "pharmacogenetics-based dosing" and "pharmacogenomic testing" for "pharmacogenomics", and terms like "mental illness", "psychological disorders", and

"behavioural disorders" for "psychiatric disorders". We used appropriate Boolean operators "AND" and "OR" to combine the keywords. In addition to the electronic database search, we also hand-searched the reference lists of the included studies, but no additional studies were identified. The findings of this systematic review were presented in accordance with the reporting guidelines of Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) (29).

Selection criteria and data extraction

The two reviewers (MBA and AM) evaluated all the articles identified through our search strategy for eligibility based on predefined criteria, which included being conducted in African populations and focusing on pharmacogenomics or pharmacogenetics of psychiatric disorders. We also included studies that were published in English and had full-text availability. In case of disagreement between the two reviewers, a third reviewer (ATA) was consulted to reach a consensus on eligibility. All retrieved records were exported in an Endnote library (version 20) for further analysis.

We used a customized data extraction template to collect relevant information from the selected articles. The two primary reviewers (MA and AM) used this template to summarize the articles, and the extracted data included authors, year of study, sample size, participant ancestry, psychiatric condition studied as an outcome of interest, type of medication studied, and reported gene/allele of the pharmacogenomic test. The extracted data were double-checked by ATA to ensure accuracy. We extracted data on the main indicators of pharmacogenomics/pharmacogenetics of psychiatric disorders.

Risk of bias assessment

We used a comprehensive search strategy involving multiple databases to identify relevant studies. The inclusion and exclusion criteria applied in the search were designed to ensure that the review is based on a rigorous and comprehensive search for relevant studies. The details of the search strategy, inclusion and exclusion criteria, and results of the literature search are provided in additional file 1: Supplementary methods for transparency and to enable replication of the review.

Result

The initial literature search in three databases resulted in a total of 1767 articles. After removing duplicates, 1090 records related to pharmacogenetics and pharmacogenomic studies remained. These records underwent screening by two independent reviewers who evaluated their titles and abstracts. From this process, a total of 42 studies, including 35 studies on pharmacogenetics and 7 studies on pharmacogenomics, were deemed to have potential relevance and were consequently retrieved in full text for the purpose of this systematic review. Figure 1 displays a flow diagram of the literature review, illustrating the study selection process and delineating the number of records that were screened initially, excluded, and ultimately included in the final review.



Figure 1. A schematic diagram illustrating the steps undertakes to screen articles for a systematic review on the pharmacogenomics of psychiatric disorder in African population.



Figure 2. Distribution of pharmacogenomics and pharmacogenetics studies in patients with psychiatric disorder across Africa

Our review found a considerable variation in the distribution of psychiatric pharmacogenomic studies across Africa. Countries such as South Africa, Zimbabwe, Uganda, Tunisia, Ghana, and Algeria have made comparatively larger research contributions than others. Of all the studies reviewed, the largest proportion of the studies (21%) were conducted in East African regions, followed by the Southern regions of Africa (20%) and the North African region (10%). The West African region was represented by approximately 12% of the studies, while the Central African region had the smallest proportion, accounting for less than 1% of the total. It has been reported that 37% of the studies involved individuals with multi-ethnic backgrounds. These studies encompassed specific countries, as illustrated in the map depicted below (Fig. 3).

Fig. 3. Countries in Africa where psychiatric pharmacogenomic studies have been conducted.

Psychiatric Pharmacogenomics in African populations

Pharmacogenomic research has predominantly centred on Cytochromes P450 (CYPs), a group of enzymes that play a critical role in drug metabolism and treatment outcomes, including psychiatric medications (30). Table 1 provided pharmacogenomic studies included in this review detailing identified genes, psychiatric conditions, type of medication studied, country where the study conducted, population studied, and summary of the findings. Within African populations, psychiatric pharmacogenomics research has predominantly centred on individuals diagnosed with SCZ and MDD. This body of evidence indicates substantial genetic diversity exists in the core ADME (Absorption, Distribution, Metabolism, and Excretion) and extra ADME genes, not only within but also between individuals of African and European ancestry, emphasizing the requirement for tailored PGx programs that accommodate population specific genetic variations.

Psychiatric Pharmacogenomics in patients with Schizophrenia: Ammar H et al., in their study using xxx Tunisian patients with SCZ, they revealed the benefits of genotyping the *CYP1A2* gene and the use of therapeutic drug monitoring (TDM) to enhance the effectiveness and safety of Clozapine(31). This study found a significant association between the *CYP1A21*□F* polymorphism and Clozapine metabolism, accounting for 24% of the variability in Clozapine concentration-to-dose ratio. Moreover, the *CYP1A2 -163C>A* variant plays a crucial role in the variation of Clozapine exposure (31).

Radouani et al., discovered associations between *CYP2C19* haplotypes and inadequate treatment response to XXX in patients with SCZ (32). Furthermore, these studies have reported differences in the prevalence of CYP genetic variants between African populations and other populations worldwide, underscoring the importance of considering population-specific evidence for clinical translation.

In a study by Campbell et al., the presence of genetic variants within *RGS4* gene (rs2661319 and rs2842030) were found to predict relative responsiveness to antipsychotics treatment (perphenazine) (33). This study reported that in individuals of African ancestry who were homozygous for 'C' allele of rs951439 in *RGS4* gene had a better response to the atypical antipsychotic (perphenazine) compared to quetiapine or ziprasidone (33).

A study involving patients with first-episode of SCZ from Xhosa populations in South Africa identified a frameshift variant, rs11368509 in *UPP2* gene associated with improved treatment

outcome to anti-psychotic medications (34). Drogemoller's et al., revealed the synonymous polymorphism rs1049353 in *CNR1* gene associated with a higher weight gain in African American schizophrenic patients treated with clozapine and olanzapine. The allelic analysis of rs1049353 ('CC' vs 'CT' allele) demonstrated that patients who carried the 'C' allele gained more weight compared to those with 'T' allele (35). In another study involving South African patients with first-episode SCZ, rs13025959 in the *MYO7B* gene and rs10380 in the *MTRR* gene were associated with different aspects of treatment response. The 'C' allele of rs13025959 was linked to reduced improvement in general psychopathological symptoms after antipsychotic treatment, while the 'T' allele of rs10380 was associated with an improvement in positive symptoms (36).

In South African patients with SCZ, O'Connell et al., found that *DNMT3A* rs2304429 'CC' genotype was associated with an improved treatment response when compared to the 'TC' allele (37). On the other hand, the *HDAC5* rs11079983 'TT' genotype was associated with a poorer treatment response when compared to the 'CC' genotype. Patients with the *HDAC9* rs11764843 'CA' or *HDAC9* rs1178119 'GA' genotype had a slower rate of reduction in negative symptom scores over time on the Positive and negative Syndrome Scale (PANSS) than patients with the 'AA' genotype (37). In African Americans taking risperidone (atypical antipsychotic), the *GRM3* SNP-rs724226 was associated with a change in the PANSS total score, while the *COMT* SNP-165599 was moderately associated with a change in the PANSS negative score for patients on risperidone treatment. In addition, there was a significant association between rs1801028, a SNP in *DRD2*, and PANSS negative symptoms in African Americans. Moreover, the change in the PANSS negative total increased as the number of 'G' alleles increased among African-American patients with 'AA', 'AG', and 'GG' genotypes (38). Hwang et al., in their study on African American populations, specific *DRD2* variants, such as *Taq1A*, *Taq1B*, and rs1125394, have been associated with an improved response to clozapine. Of particular note, significant differences in the frequencies of the *Taq1B* allele were observed between responders and non-responders, with the "B2" allele being associated with a better response. Similarly, significant differences in allele frequencies were also found at two other marker sites, with allele 1 of rs1125394 being more frequent in responders, and the "A2" allele for *Taq1A*. However, no significant association was found between clozapine response and the -141C insertion/deletion (ins/Del) site (45).

This is a rare type of convergence between the candidate gene and the SCZ genes as a result of inadequate statistical power in candidate genes (39). Genetic variants within *COMT*, one of

the historical candidate gene for SCZ, has not shown a significant association in large European (40) and African-Americans (41) ancestry samples.

Benmessaoud et al., in their study on Algerian patients with SCZ have found that those who carry the 'G' allele for a gene that codes for the 5-HT2A receptor, one of the targeted receptors for antipsychotic drugs, exhibit a favourable response to conventional antipsychotics (42). The authors of the study have highlighted that the 'G' allele identifies a subgroup of schizophrenic patients who are more likely to experience symptom improvement with antipsychotic drugs, emphasizing the significance of this finding (42).

A study in South African patients with SCZ examined the association of noncoding genetic variants within the *MANBA*, *COL9A2*, and *NFKB1* with treatment response. Of the three SNPs identified, rs230493 and rs230504 were associated with poorer PANSS negative score, while rs3774959 was associated with poorer PANSS negative and PANSS total scores. This study further confirms that these significantly associated variants were present in the 4q24 region (43) which is known for ???.

The CLOZUK study found that people with sub-Saharan African ancestry metabolized clozapine and norclozapine faster than people with European ancestry (47). However, a study by Dodgen et al., on a South African cohort taking risperidone found no significant association between poor metabolism of *CYP2D6* and adverse reactions to the drug. Furthermore, a novel *CYP2D6* variant, *3877G>A* have not shown impact on metabolism of risperidone. These findings suggest that *CYP2D6* variants may not be a reliable pharmacogenetic indicator for predicting risperidone-related adverse events in South Africans (46).

Psychiatric Pharmacogenomics in patients with depression: Another emerging area of research in African psychiatric pharmacogenomics focuses on studying genetic factors influencing drug metabolism and response among individuals with MDD. For instance, studies utilizing data from sub-Saharan African patients with MDD have indicated the presence of the *CYP2C19**2 loss of function allele, which was likely due to the administration of haloperidol, a weak *CYP3A4* inhibitor that interact with voriconazole (48). In a study by Binder E.B. et al., it was discovered that the variant rs10473984 within the *CRHBP* locus was associated with both remission and reduction in depressive symptoms in patients taking citalopram, particularly those with features of anxious depression (REF). However, in African Americans, despite a larger difference in minor allele frequency, the

rs10473984 'T' allele was associated with poorer treatment outcomes (49). Eleanor Murphy et al., reported an association between genetic African ancestry and self-reported race with poor treatment response to citalopram (50).

A study on South African patients taking amitriptyline found that a genetic variant, *2509G>T* in *CYP2D6*2/*29* genotype resulted in an amino acid change (*K245N*) and amitriptyline treatment-related side effects (51). Another study focused on *CYP2D6* genetic variants related to tramadol treatment (fast acting medication for MDD) in an African population revealed a significant difference in the maximum plasma concentrations of the active metabolite (+) R, R-O-desmethyltramadol between the ultra-metabolisers (UMs) and extensive metabolisers (EMs). UMs exhibited an increased pain threshold and tolerance compared to EMs and nearly 50% of the UM group experienced nausea compared to only 9% of the EM group (52).

Pharmacokinetic genes of African population

This review found that African patients exhibit high variability in their drug metabolism gene profile, which can influence their pharmacological treatment outcomes, including psychiatric medications. Studies conducted in Tanzania, Zimbabwe, Sudan, Somalia, Burundi, Ethiopia, and South Africa demonstrated the wide variability in the frequency of various CYP family genes such as *CYP2D6*, *CYP2C19*, *CYP3A4*, *CYP2B6*, *CYP2*, and *CYP1A2* (21). Many of the pharmacogenes studied in the African population belong to the highly polymorphic gene of *CYP2D6* that involved in the metabolism of up to 25% of the drugs that are commonly used in psychiatric conditions (53). For instance, in a study of Tanzanian psychiatric patients, healthy Tanzanian controls, and South African Venda populations, Bathum et al., reported that the *CYP2D6* genotype was found to predict poor metabolisers in only a small percentage of cases 2.3%, 1.9%, and 2.6%, respectively. Notably, in the Tanzanian population, the frequency of the low-activity *CYP2D6*17* allele was significantly higher among psychiatric patients (30%) compared to healthy individuals (20%). In healthy Tanzanian individuals, EMs exhibited a significantly higher sparteine metabolic ratio compared to white Danish EMs. The frequencies of the *CYP2D6*1* and *CYP2D6*4* alleles were 9.6% and 4.0%, respectively, and no *CYP2D6*3* alleles were found. The frequencies for the *CYP2C19**1 and *CYP2C19*2* alleles was 9.0%, 1.0% , respectively (54). Moreover, Wright, G. E. et al. identified a unique allele distribution and two rare novel alleles, *CYP2D6**73 and *CYP2D6**74 in South African participants (55). With this pharmacogene, genotyping of black Zimbabwean population on *CYP2D6* showed that the frequency of three genes, *CYP2D6*A*,

*CYP2D6*B*, and *CYP2D6*D*, was determined to be 0%, 1.8%, and 3.9%, respectively. None of the subjects carried the Xba I 44 kb haplotype, which is a known *CYP2D6* allele indicative of poor metabolisers in Caucasians (56). The *CYP2D6*B* allele frequency was very low in the Zimbabwean population (57).

The other pharmacogene wherein many African population were studies was the *CYP2C19* gene that contribute to the metabolism of a large number of clinically relevant drugs and drug classes such as antidepressants, benzodiazepines, mephenytoin, proton pump inhibitors (PPIs) (58). Dandara et al., reported that the prevalence of poor metabolisers was determined by the frequencies of *CYP2C19*2* genotypes, which were found to be low. Interestingly, the *CYP2C19*3* allele was not detected in any of the three studied populations, South Africa (Venda), Tanzania, and Zimbabwe (59). No significant difference was observed in the frequency of *CYP2D6* or *CYP2C19* poor metabolisers genotypes between psychiatric patients and healthy individuals (59). Persson I et al., who examined the *CYP2C19* profile on 140 Ethiopians found that 5.2% of them were poor metabolisers of S-mephenytoin, with a frequency of 0.14 for *CYP2C19*2* allele and 0.02 for *CYP2C19*3* allele. Among the poor metabolisers, three were homozygous for *CYP2C19*2*, and the remaining three were heterozygous for both *CYP2C19*2* and *CYP2C19*3*. Furthermore, the *CYP2C19*2* and *CYP2C19*3* alleles accounted for all defective *CYP2C19* alleles among the Ethiopian poor metabolisers (60). Sim Sc et al., who studied Ethiopians found that individuals homozygous for the *CYP2C19*1* allele had a different S/R-mephenytoin ratio than those homozygous for *CYP2C19*17* and suggest the potential implication of this variant to antidepressants treatment (61). In Ugandans, the frequency of the *CYP2C19*1, *CYP2C19*2, *CYP2C19*3, and *CYP2C19*17 alleles was 69.2%, 12.6%, 1.0%, and 17.2%, respectively (62). Similarly, C. Masimirembwa et al., studied 103 Zimbabwean adults on *CYP2C19* found that out of 103 subjects, four individuals were identified as poor metabolisers. Among 84 subjects who were phenotyped for mutation in exon 5 of *CYP2C19*, the mutation creates a cryptic splice site and results in a non-functional protein. While three of the four poor metabolisers were found to be homozygous for mutation in exon 5 of *CYP2C19*, one was heterozygous suggesting that a mutation in exon 5 is predictive of the occurrence of more than 60% of poor metabolisers in black populations (63). In a study in Burundi, it was reported that 5% of the population were classified as poor metabolisers (64).

The other important pharmacogene studied was the hepatic and extra-hepatic pharmacogene of *CYP3A4*. This gene together with *CYP3A5* account for 30% of the hepatic cytochrome

P450, and half of medications that are oxidatively metabolised by liver are *CYP3A* substrates (65). Mouterde, et al. reported that Ethiopians have a fast P-glycoprotein transport activity, with a higher rate for midazolam (*CYP3A4*) and bupropion *(CYP2B6)* (66). On the other hand, a study comparing two ethnic groups in Botswana showed a significantly higher prevalence of the *CYP2C8**2 allele in the San (or Bushmen) than the Bantu-related ethnic groups (67).

C. M. Masimirembwa et al., reported that many rural black children had lower indexes of *CYP1A2* activity, indicating that the average value was significantly lower than that of healthy white urban children from Zimbabwe, as well as healthy Canadian adults. They also indicated that the low *CYP1A2* activity of rural Zimbabwean children calls for medical studies and suggests a widespread, and perhaps serious, impairment of certain liver functions (56). Bayoumi RAL, et al., who studied 136 Sudanese individuals found that eight of them were found to be heterozygous for the *G191A* mutation, resulting in a frequency of 0.02.9%. However, none of the 50 Somali individuals tested carried the *G191A* mutation (68). The Human Leukocyte Antigen (HLA) alleles were also examined in African population for its role of pharmacogenetics of drug hypersensitivity (69). The A study of samples from the Somali population by Ali et al., identified as the *UGT1A4*2* variant had the highest frequency, and this population exhibited unique HLA characteristics distinguishing them from neighbouring regions and the *HLA-DR-DQ* haplotype was a predictor of metabolic diseases (70).

Table 1. Psychiatric pharmacogenomics among individuals of African ancestry

Author (Year)	**Country (N)**	**Drug**	**Treatment outcome (Phenotype)**	**Gene**	**Psychiatric disorder**	**Summary**
Benmessaoud, D. et al., (2008)(42)	Algeria (88)	Antipsychotics (mainly Haloperidol) for 4 weeks	Treatment-refractory schizophrenia (TRS)	G allele of the -*1438A/G 5-HTR2A*	SCZ	The -1438A/G polymorphism *5-HT2A* receptor gene showed association with a favourable response to typical antipsychotics. The 'G' allele identified individuals with SCZ who have a higher likelihood of responding to antipsychotics.
Campbell, D. B. et al., (2008)(33)	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Out of 678 subjects 198 were African only	Perphenazine and Quetiapine	Antipsychotic treatment efficacy, assessed using Positive and Negative Symptoms Scale (PANSS)	*RGS4* (rs2661319, rs2842030) for baseline PANSS total score. rs951439 'C' allele for treatment response in African ancestry	SCZ	*RGS4* genotypes predicted treatment response. For individuals of African ancestry with rs951439 'C' allele homozygosity, perphenazine was more effective than quetiapine (p=0.010) or ziprasidone (p=0.002).
Drögemöller et al., (2015)(36)	South Africa (190)	Flupentixol decanoate	PANSS scale	rs13025959 in *MYO7B* (E1647D) and rs10380 in *MTRR* (H622Y)	First episode SCZ	rs13025959 in *MYO7B* gene was linked to a reduced progress in overall psychopathological symptoms following antipsychotic treatment. rs13080 in *MTRR* was associated with an improvement in positive symptoms after antipsychotic treatment.
Ammar, H. et al., (2021)(31)	Tunisia (51)	Clozapine	Therapeutic drug monitoring (Variability in mean dose adjustment of clozapine).	*CYP1A2*1F* (rs762551; -163C>A), *CYP1A2*1C* (rs2069514; -3860 G>A) and *CYP 2C19*2* (rs4244285; *681G>A)*	SCZ	*CYP1A21*F* and CYP1A2 -163C>A variants were linked to variation in Clozapine exposure among Tunisian patients with SCZ. *CYP1A21*F* alone explained 24% of the variability in Clozapine C0/D. The authors recommended genotyping *CYP1A2* and using therapeutic drug monitoring (TDM) to improve Clozapine's effectiveness and safety in treating SCZ patients.

Drögemöller et al., (2014)(35)	Mixed ancestry of first-episode SCZ (n=103) and Xhosa (n=222) population in South Africa	Antipsychotic	Treatment response	rs11368509	SCZ	A frameshift variant, rs11368509 in *UPP2* found to be associated with improved treatment response to anti-psychotics in mixed ancestry (p=0.057) and South African Xhosa populations (p=0.016)
Ovenden, E. S. et al., (2017)(43)	South African (103)	Flupentixol decanoate	Percentage change in PANSS	*MANBA*, *COL9A2* and *NFKB1*	SCZ	Noncoding variants on *MANBA*, *COL9A2*, and *NFKB1* were examined for their treatment response in antipsychotic response. Three SNPs (rs230493, rs3774959, and rs230504) were associated with poor treatment response in SCZ.
O'Connell, K. S., et al., (2019)(37)	South African (20)	Flupentixol decanoate	Differential expression of regulatory genes to identify candidate genes for association with antipsychotic treatment response.	(*DNMT3A* rs2304429, *HDAC5* rs11079983, and *HDAC9* rs1178119 and rs11764843	SCZ	Four variants within differentially expressed genes (*DNMT3A* rs2304429, *HDAC5* rs11079983, and *HDAC9* rs1178119 and rs11764843) were significantly associated with treatment response in SCZ. Two of these variants altered the expression of specific genes in brain regions previously implicated in SCZ and treatment response, potentially aiding in the development of biomarkers and novel drug targets for antipsychotic treatment response.
Antonio F Pardinas et al., (2023)(47)	CLOZUK study (192)	Clozapine	Clozapine and norclozapine plasma concentrations	*for Clozapine [DNAJB3, MROH2A, UGT1A1, UGT1A3, UGT1A4,* UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, *CYP1A1, CYP1A2]; for Norclozapine [UGT2A3, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B28, DNAJB3,*	SCZ	Individuals of sub-Saharan African ancestry showed lower levels of clozapine (beta -0.088) and norclozapine (beta -0.280) in their plasma compared to Europeans, indicating that they metabolize these drugs faster.

				MROH2A, UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, CYP1A1, CYP1A2]		
Motta, I. et al., (2015)(48)	A case report from Sub-Saharan Africa	Voriconazole and haloperidol	Drug-drug interaction between voriconazole and haloperidol	*CYP2C19*	MDD	The presence of the *CYP2C19*2* loss of function allele may be the cause of an interaction that can be explained by the introduction of haloperidol, which is a mild inhibitor of *CYP3A4*.
Merwe, N. V. D. et al., (2012)(71)	South Africa. 114 (52 Caucasians and 62 coloured)	Cipramil, cipralex, bupropion and Tamoxifen	Genotyping for *CYP2D6* genes and concomitant use of Tamoxifen.	*CYP2D6*4*, rs3892097	MDD	*CYP2D6* genotyping can help identify high-risk breast cancer patients who may experience cumulative effects from the concurrent use of Tamoxifen and antidepressants that can interact with each other.
Eleanor Murphy et al., (2013)(50)	Blacks (299)	Citalopram	Reduction in depressive symptoms using QIDS scores	Genome wide SNP data	MDD	Genetic African ancestry found to be associated with poor treatment response to citalopram.
Mamoonah Chaudhry et al., (2017)(51)	South African (31)	Amitriptyline	Gene profile of *CYP2D6* using a modified tetramer multiplex assay	*CYP2D6*	MDD	The variant 2509G>T in exon 5, which causes amino acid changes (K245N), was observed in a *CYP2D6*2/*29* genotype in South African patients experiencing amitriptyline-related side effects. This suggests that *K245N* may reduce *CYP2D6* function towards amitriptyline.
Dodgen, T. M. et al., (2015)(72)	South African	Risperidone	*CYP2D6* on adverse drug reactions	*CYP2D6*	MDD	*CYP2D6* poor metabolism was not found to be significantly associated with risperidone ADRs in a South African cohort study. However, an inverse relationship between extrapyramidal symptoms (EPS) and weight gain was observed. A new *CYP2D6* allele was identified, but it is unlikely to affect metabolism based on in silico evaluation. The study suggests that *CYP2D6* variation may not be a reliable pharmacogenetic marker for predicting risperidone related ADRs.

Ajmi, M. et al., (2018)(73)	Tunisia (153)	Antiepileptic drugs	Genotyping of the *ABCB1* gene using polymerase chain reaction-restriction fragment length polymorphism.	ATP-Binding Cassette sub-family B, member 1 (*ABCB1*) polymorphisms: *C1236T* (rs1128503), *G2677T* (rs2032582) and *C3435T* (rs1045642)	Resistance to Antiepileptic drugs	Two polymorphisms (*G2677T* 'T' and C3435T 'T') of the *ABCB1* gene increase the risk of developing AEDs resistance, while the *C1236T* 'T' allele does not appear to influence the response to AEDs.
Kirchheiner, J. et al., (2008)(52)	Northern African (22)	Tramadol	Pharmacokinetic profile for *CYP2D6*, Tramadol as a probe	*CYP2D6*	Opioid adverse events	Ultra-rapid metabolisers (UMs) of tramadol showed significantly higher levels of the active metabolite (+) R,R-O-desmethyltramadol in their plasma, as well as increased pain threshold and pain tolerance, stronger miosis, and higher incidence of nausea compared to extensive metabolisers (EMs).
Médéric Mouterde et al., (2022)(66)	Ethiopia (349)	(Caffein, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine), as well as the P-glycoprotein substrate	Drug metabolism phenotype using seven probe compounds	CYP enzymes (*CYP1A2*, *CYP2B6*, *CYP2C9*, *CYP2C19*, *CYP2D6*, and *CYP3A4*)	Drug - metabolizing gene profile	Ethiopian were fast in the P-glycoprotein transport activity. Higher rate in Ethiopian for midazolam (*CYP3A4*) and *CYP2B6* for bupropion
Ali, A. A. et al., (2020)(70)	Somali (95)	Axiom Array Analysis Suite, version 4.0.3.3	Genotype frequency of *HLA* in Somali population	*HLA-DR-DQ* and *UGT1A4*2*	Drug-metabolizing gene profile	Somali population displays genetic traits of significance to health and disease. *UGT1A4*2* highest frequency reported in this population. This population reported to have unique human leukocyte antigen (*HLA*), which seem to differentiate from all other neighbouring regions. *HLA-DR-DQ* haplotype predisposing for T1DM

Afilal, D. et al., (2017)(74)	Morocco (290)	Restriction fragment length polymorphism-polymerase chain reaction genotyping method	genotype frequency of *CYP2C9* and *CYP2C19*	*CYP2C9*2* and *CYP2C19*2*	Drug-metabolizing gene profile	The *CYP2C9*2* and *CYP2C19*2* were the most common alleles, respectively with frequencies of 8% and 11.4%. Regarding *CYP2C9*2* and *CYP2C19*2*, approximately 16% and 22% of Moroccans are respectively deficient metabolisers, and thus largely lack this enzymatic activity. Our results suggest that only *CYP2C9*2* and *CYP2C19*2* are likely to substantially contribute to individual and interethnic variability of *CY2C9-19* activity in our population.
Adehin, A. et al., (2017)(75)	Nigeria (100)	Sequenom MassARRAY platform for some allele and Sanger sequencing for others	Genotype frequency and relationship of *CYP1A2* and *CYP2A6*	*CYP1A2* and *CYP2A6*	Drug-metabolizing gene profile	The five *CYP1A2* haplotypes identified in the Nigerian population were not predictive of metabolic phenotypes, and heterozygous *CYP1A2*1J* carriers and homozygous *CYP1A2*1W* carriers showed a statistically insignificant decrease in *CYP1A2* activity. The *CYP2A6*9/17* genotype was significantly associated with the *CYP2A6*-poor metabolic phenotype, while *CYP2A6*11* was not detected in the population.
Adehin, A. et al., (2017)(76)	Nigeria (178)	Sequenom iPLEX MassARRAY platform	Genotype frequency of *CYP2C8* and *CYP3A5*	*CYP2C8* and *CYP3A5*	Drug-metabolizing gene profile	*CYP2C8*2* was present in about 19.4% of the population, while *CYP3A5*3*, *CYP3A5*6*, and *CYP3A5*7* were present in 16.0%, 9.6%, and 12.6% of the population, respectively. *CYP2C8*3* was not detected. The prevalence of at least one *CYP3A5* polymorphism was found to be 60%, indicating potential variability in *CYP3A5* activity that could impact drug metabolism and dosing.
Motshoge, T. et al., (2016)(67)	Botswana (544)	PCR-based restriction fragment length polymorphism analysis	Genotype frequency of *CYP2C8*2*	*CYP2C8*2*	Drug-metabolizing gene profile	Prevalence of the *CYP2C8*2* allele is significantly higher among the San population compared to Bantu-related ethnic groups. The results suggest a different genetic background between the two populations, which may have implications for drug clearance and activation among the San group.

Wright, G. E. et al., (2010)(55)	South African (15)		Genotyping *CYP2D6* frequency	*CYP2D7*	Drug-metabolizing gene profile	A unique allele distribution was revealed and two rare novel alleles, *CYP2D6*73*, and *CYP2D6*74*, were identified.
Santovito, A. et al., (2010)(77)	North Ivory Coast (133)		Genotype frequency for *CYP1A1, GSTM1, and GSTT1*.	*CYP1A1, GSTM1, GSTT1*	Drug-metabolizing gene profile	Frequencies of *GSTM1* and *GSTT1* null genotypes were 0.361 and 0.331, respectively. No significant differences were noted between men and women. In contrast to published data for Africans, *CYP1A1 *Val* Allele frequency (0.383) was significantly high ($p < 0.001$) in this specific population. For the *GSTT1* null genotype, no differences were found between the studied and other African populations, the contrary to what occurred for the *GSTM1* null genotype in relation to Gambia and Egypt.
Miura, J. et al., (2009)(62)	Ugandans (99)		Genotype frequency for *2C19* genes	*CYP2C19*	Drug-metabolizing gene profile	The frequency (95% confidence interval) of the *CYP2C19*1*, *CYP2C19*2*, *CYP2C19*3* and *CYP2C19*17* alleles in Ugandans was 0.692 (0.601–0.783), 0.126 (0.061–0.192), 0.010 (not calculated due to the small number) and 0.172 (0.097–0.246), respectively.
Sim, S. C. et al., (2006)(61)	Ethiopia (126)	mephenytoin	Metabolism profile of *CYP2C19* gene profile sequencing the 5'-flanking regions.	*CYP2C19*1*	Drug-metabolizing gene profile	In Ethiopians a similar difference in the S/R-mephenytoin ratio was observed between individuals homozygous for *CYP2C19*1* (median, 0.20 [interquartile range, 0.12-0.37]) and those homozygous for *CYP2C19*17* (median, 0.05 [interquartile range, 0.03-0.06]) ($P = .013$). *CYP2C19*17* is likely to cause therapeutic failures in drug treatment with antidepressants.
Gyamfi, M. A. et al., (2005)(78)	Black Africans (105 Ghanaians, 12 Nigerians, 2 Ivorians and 1 Ugandan)	Drug metabolism	Frequency of functionally important variants of the *CYP2A6* genes	*CYP2A6*1*	Drug-metabolizing gene profile	*CYP2A6* variants such as *2, *5, *6, *7, *8, *10 and *11 was absent in these black African populations. This study provides, for the first time, the results of the analysis of *CYP2A6* allele frequency in black African populations and confirms large ethnic differences in the polymorphic *CYP2A6* gene.

Dandara, C. et al., (2001)(59)	East and Southern Africans (384)	One or a combination of Haloperidol, thioridazine, zuclopenthixol, amitriptyline, fluoxetine, chlorpromazine, fluphenazine, and imipramine	Genotype frequency of *CYP2D6* and *CYP2C19* in 3 African populations and compare healthy and psychiatric patients.	*CYP2D6* and *CYP2C19*	Drug-metabolizing gene profile	The frequency of poor metabolisers of *CYP2D6* and *CYP2C19* was low in Bantu populations of East and Southern Africa. The prevalence of *CYP2D6*17* allele was higher in Tanzanian psychiatric patients than healthy individuals. The low prevalence of *CYP2C19*2* genotypes predicted the low prevalence of poor metabolisers. However, the high frequency of the low-activity *CYP2D6*17* allele may suggest reduced drug metabolism capacity in the Bantu people.
Xie, H. G. et al., (1999)(79)	Black Africans (922)	Mephenytoin	Genotype frequency for *CYP2C19*	*CYP2C19*	Drug-metabolizing gene profile	The study found that the poor metaboliser (PM) phenotype frequency in healthy black Africans and black Americans ranged from 1.0% to 7.5%, with an overall frequency of 3.9%. The PM genotype frequency was found to be 3.7%, which agrees with the frequency of the PM phenotype. The study concluded that individuals of African descent have a low frequency of the *CYP2C19* PM phenotype and genotype, and that the defective *CYP2C19* alleles are uncommon, with only a small proportion of heterozygotes existing in the extensive metaboliser (EM) subpopulation.
Griese, E. U. et al., (1999)(80)	West Africans (201)	Debrisoquine, Sparteine	genotyping for *CYP2D6* probe drugs Sparteine and Debrisoquine.	*CYP2D6*	Drug-metabolizing gene profile	The study investigated the correlation between metabolic ratios of sparteine and debrisoquine in individuals with both drugs. The study found a significant correlation between metabolic ratios and lower metabolic clearance for *CYP2D6* substrates in West Africans compared to Caucasians. The study also identified a poor metaboliser for sparteine and debrisoquine with the *1/*1 genotype and discovered the existence of unknown non-functional alleles in the West African population.

Bathum, L. et al., (1999)(54)	Tanzanians (216)	Sparteine, mephenytoin, proguanil	Determine defective *CYP2D6* and *CYP2C19* genes and test correlations with proguanil/cycloguanil ratio than mephenytoin S/R ratio.	*CYP2D6, CYP2C19*	Drug-metabolizing gene profile	The study found that Tanzanian extensive metabolisers had higher sparteine metabolic ratio than white Danish extensive metabolisers, with only one poor metaboliser for *CYP2D6* found. Seven subjects were phenotyped as poor metabolisers for *CYP2C19*, but only three had a genotype indicative of poor metabolism. The study concluded that African black populations and Caucasian populations have substantial differences in drug metabolism capacity for *CYP2D6* and *CYP2C19*.
Bayoumi, R. A. L. et al., (1997)(68)	Sudanese (136) and Somali (50)		Genotype for N-acetyltransferase mutation	*G191 A*	Drug-metabolizing gene profile	Out of the 136 Sudanese individuals tested, eight were found to be heterozygous for the *G191* A mutation, resulting in a frequency of 0.029. The *G191* A mutation was not found in any of the 50 Somali individuals tested. When the chi square test was performed, it was observed that the frequency of the *G191* A mutation overlapped among Sudanese, Somalis, and Emirates.
Persson, I. et al., (1996)(60)	Ethiopians (114)	S-mephenytoin	*CYP2C19* Genotype	*CYP2C19*	Drug-metabolizing gene profile	Study found 5.2% of subjects were poor metabolisers of S-mephenytoin. *CYP2C19*2* allele frequency was 0.14, *CYP2C19*3* allele was 0.02, accounting for all defective *CYP2C19* alleles among Ethiopian PMs. PM frequency similar in Ethiopians, Zimbabweans, and Caucasians.
Horsmans, Y. et al., (1996)(81)	Zaire (8)	mephenytoin, phenytoin, and tolbutamide	Metabolism of the three drugs by *CYP2C9/10* and *CYP2C19*.	*CYP2C19, CYP2C9/10*	Drug-metabolizing gene profile	This study found a significant correlation between phenytoin and tolbutamide oxidation in black Africans, suggesting that they may be hydroxylated by the same CYP enzyme(s) in this population. However, there was no correlation between mephenytoin oxidation and either phenytoin or tolbutamide oxidations.
Masimirembwa, C. M. et al., (1995)(56)	Zimbabwe (45)	Caffeine	Activity of hepatic enzyme *CYP1A2*, xanthine oxidase and N-acetyltransferase-2	*CYP1A2*	Drug-metabolizing gene profile	Rural black children in Zimbabwe had significantly lower *CYP1A2* activity than healthy white urban children from Zimbabwe or Canada, as well as healthy Canadian adults. This suggests a possible impairment of certain liver functions

						and calls for medical studies.
Masimirembwa, C. M. et al., (1995)(63)	Zimbabwe (103)	S-mephenytoin	Enzymatic activity of *CYP2C19*.	*CYP2C19*	Drug-metabolizing gene profile	Four individuals (4%) were identified as poor metabolisers. Three of the four poor metabolisers were found to be homozygous for the G-->A mutation in exon 5 of *CYP2C19*, which is predictive of the occurrence of more than 60% of poor metabolisers in black populations.
Masimirembwa, C. M. et al., (1993)(57)	Zimbabwe (114)		Genotyping of *CYP2D6* using Eco RI and Xba I RFLP, and allele specific PCR amplification.	*CYP2D6*	Drug-metabolizing gene profile	The frequency of *CYP2D6*A*, *CYP2D6*B*, and *CYP2D6*D* genes was 0%, 1.8%, and 3.9%, respectively, in the Zimbabwean population. No poor metaboliser haplotypes were found, but five individuals had the 29/42 kb haplotype. *CYP2D6*B* allele frequency was very low, suggesting a possible Caucasian origin of the allele. These findings suggest differences in the *CYP2D* locus among ethnic groups.
Nsabiyumva, F. et al. (1991)(64)	Burundi (100)	Dextromethorphan	Determining oxidation of the drug	*CYP450*	Drug-metabolizing gene profile	5% of the Burundian populations were poor metabolisers

Discussion

This article presents a systematic review of the status of psychiatric pharmacogenomics in African populations, highlighting the challenges and opportunities for expanding future research efforts in the region. The high genetic variability of African populations is well-documented (82), and this variability and its impact on the way drugs are metabolized and affect treatment effectiveness might differ between populations. By studying the unique genetic characteristics of African populations, researchers have attempted to present novel insights into how the effectiveness of drugs can be influenced by genetic variations. These studies have the potential to advance global efforts in pharmacogenomics and improve health outcomes not only for people of African descent but also for individuals of all races and ethnicities around the world.

In Africa, the field of pharmacogenomics is evolving very slowly and the number of published studies on psychiatric pharmacogenomics is relatively low; as such, the translation of these findings into clinical practice is very limited compared to other regions of the world (83). Within Africa regions, the extent of research in the field of psychiatric pharmacogenomics varies among different countries. For example, eastern and southern African countries, specifically Zimbabwe and South Africa, have published more studies compared to western Africa (REF). The main reasons for these disparities may include differences in access to research funding, infrastructure, expertise, as well as sociocultural and ethical considerations that affect the feasibility of conducting genomic research.

In this review, we assessed 42 studies that explored the impact of pharmacogenomic and pharmacogenetic factors on drug response, remission rates, and drug metabolism in individuals diagnosed with major psychiatric disorders, including SCZ, MDD, and BD. Studies involving individuals with SCZ have identified several genetic variations within genes such as *CYP2C9*, *CYP2C19*, *MYO7B*, *MTRR*, *RGS4*, *CYP1A2*, and *CYP1A*21F* associated with treatment outcomes and influencing drug metabolism (37, 43, 84). For instance, the CLOZUK study found that individuals of sub-Saharan African ancestry metabolize clozapine faster, which has implications for dosing and treatment efficacy of this drug (47). While not much work has been done on the African continent, studies such as ClozUK and others involving diaspora Africans may provide a better basis for comparison in

African-based studies. For example, polygenic scores in diaspora Africans may serve as more suitable comparators than non-African summary statistics (85). Moreover, cytochrome P450 enzymes, such as *CYP2D6*, *CYP1A2*, and *CYP3A4/5*, play a crucial role in the metabolism of antipsychotic medications, and the polymorphic alleles of these proteins are associated with altered plasma levels of these medications (86). As approximately 40% of antipsychotics are metabolized via *CYP2D6*, 23% via *CYP3A4* and 18% via *CYP1A* (87), pharmacogenomic testing can be useful in guiding drug therapy for better treatment outcomes.

The scope of this review extends to pharmacogenomic studies exploring various candidate genes that have been implicated in influencing susceptibility to adverse drug reaction (ADR). Adverse drug reaction (ADR) is defined as a harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product (88). The inclusion of ADR as part of drug response criteria is of paramount importance in assessing the efficacy and safety of medications. One such example from this review is the *CYP2D6*2/*29* genotype, where the variant 2509G>T causes amitriptyline treatment-related side effects in South African patients. This indicates that genotyping for this variant could help identify patients at risk for adverse drug reactions to amitriptyline (51). Moreover, considerable progress has also been made in identifying genetic risk for adverse drug reaction to antipsychotic drugs. For example, QT prolongation in NOS1AP has been observed in patients taking antipsychotic drugs (89). Asians carrying specific genes have also experienced adverse reactions to medications. For example, *HLA-B*15:02* carriers among East Asians have a 172□fold increased risk of Stevens□Johnson syndrome and toxic epidermal necrolysis with carbamazepine use (90). In addition, Asians have a 5.8-fold increased risk of QT prolongation when taking citalopram. As a result, the clinical pharmacogenetics implementation consortium (CPIC) guideline for selective serotonin reuptake inhibitors (SSRI) recommends reducing the dose of citalopram and sertraline by 50% in Asians who are poor metabolisers of *CYP2C19*2* and *CYP2C19*3* (17). Taken together, these findings highlight the importance of including ADR in pharmacogenomics studies. By identifying genetic variants associated with specific treatment related adverse drug reaction, researchers and clinicians can improve patient care by implementing personalized treatment strategies, minimizing the occurrence of ADRs, and maximizing drug efficacy.

The comparison of drug metabolism-related genes between psychiatric patients from Tanzania and South Africa has provided valuable insights into the pharmacogenetics of

cytochrome enzymes in African populations. The study revealed that the Bantu people of East and Southern Africa have a low prevalence of individuals with deficient *CYP2D6* and *CYP2C19* activity, but a high frequency of the low-activity *CYP2D6*17* allele. As many drugs used in psychiatry are metabolised by *CYP2D6* and *CYP2C19* enzymes, this finding has significant implications for drug metabolism (91). Understanding the pharmacogenetics of these enzymes in African populations can help clinicians optimize treatment for patients and avoid adverse drug reactions.

Furthermore, various studies have demonstrated the impact of genetic differences between ethnic groups on liver function and drug metabolism (92, 93). For example, a study conducted in Botswana compared the prevalence of the *CYP2C8*2* allele between San and Bantu-related ethnic groups and found that the San group had a significantly higher prevalence. This suggests that the presence of genetic variation within African populations, which could affect drug metabolism, clearance, and potentially determine treatment outcomes (82). This highlights the significance of therapeutic drug monitoring (TDM) in optimizing pharmacotherapy for psychiatric patients in Africa (94). TDM offers the opportunity to leverage individual variability of antidepressant pharmacokinetics to shed light on non-response and partial response, evaluate adherence, and characterize the impact of genetic and developmental variation in pharmacokinetic genes (95). For example, TDM-guided dosing of antipsychotic medications, such as olanzapine and risperidone, has been recommended as part of routine clinical practice due to its associated with improved treatment outcomes and reduced side effects (96)

Another study found that rural black children in Zimbabwe had lower indexes of *CYP1A2* activity than healthy white urban children from Zimbabwe and healthy Canadian children and adults. This finding indicates that some ethnic groups may be at higher risk for drug toxicity or treatment failure due to genetic differences in drug metabolism (97). Thus, pharmacogenetics testing is crucial to identify individuals who may require alternative drug therapies or dosing regimens (98).

The study conducted on Zimbabwean adults regarding the *CYP2C19* gene revealed that the mutation in exon 5 of *CYP2C19* resulted in a non-functional protein among adults of poor metabolisers (63). This study emphasizes the crucial need for additional research into the genetic and environmental factors underlying liver dysfunction, especially in rural areas of low- and middle-income countries. Additionally, these findings highlight the necessity of

considering the impact of lifestyle and environmental factors on drug response, given the intricate interplay between these factors in determining drug response. Future research should prioritize exploring the interactions between genes and environmental factors to enhance our comprehension (99). Ultimately, a better understanding of these factors can facilitate the development of personalized and effective drug therapy while minimizing the risk of adverse drug reactions.

The use of pharmacogenomic testing to identify these genetic variants has been found to be beneficial in white Europeans (100) and Asians (101), and African populations can also benefit from this approach in monitoring the efficacy and safety of psychiatric medications (102). Several notable examples have demonstrated the benefits of genetic-guided therapy for psychiatric patients in other ancestries. For instance, when genetic information on *CYP2D6*, *CYP2C19*, *CYP1A2*, *SLC6A4*, and *HTR2A* was used to dose patients at Mayo clinic in the United states, a significant increase in the number of responders was obtained after 8 weeks of antidepressant therapy compared to standard treatment (103). Furthermore, in another Norwegian study involving 2,066 patients, *CYP2C19* ultra metabolisers and *CYP2C19* poor metabolisers were found to be more likely to switch escitalopram to another drug (18). These examples indicate the importance of genetic-guided therapy across ancestries, including African populations. However, existing PGx data cannot be directly translated into PGx testing for African populations. Most PGx data are well characterized in populations of European and Asian ancestries, indicating a lack of evidence from African populations. Moreover, differences in linkage disequilibrium (LD) and allele frequency pose challenges to the transferability of such data.

Furthermore, the genetic diversity of ADME genes is not uniform across African populations, particularly in terms of high impact coding variation. For instance, da Rocha et al. found distinct differences between the Southern African population cluster and far West Africa, suggesting that PGx strategies based on European variants have limited applicability in African populations (104). Additionally, there is minimal genetic overlap between Europeans and Africans, with the existence of population-specific variants. Notably, functional variants in the *CYP2B6* gene contribute to a high risk of adverse drug reactions, leading to efavirenz dosage reduction for HIV patients in sub-Saharan Africa (105), and *CYP2D6* variations negatively influence the efficacy of primaquine (106, 107).

In addition allele frequency and distribution of pharmacogenomic variants vary significantly between populations and remain relatively constant within ethnically stable populations. Certain variants designated as normal are unique to specific ethnicities, such as those observed for *CYP2D6* and codeine, or *CYP3A5* and Tacrolimus (108).

While these studies provide only a partial view of the continent, they emphasize the importance of further understanding the African ADME variation and for PGx testing, it is to consider the full range of African variation, necessitating the characterization of variants in African populations through in vitro and in silico studies. Precision medicine guidelines and tools for African populations should take into account the unique ADME landscape found in Africa.

Although few, existing studies in African populations underscore the importance of genetic variation in the treatment of patients with mental illness. For example, the *DRD2* gene variant predicts the response of African Americans to clozapine, indicating the need for genotype-guided drug prescribing in patients with similar genetic properties (109). Another example is the *GRM3* SNP-rs724226, which is associated with PANSS total score in African Americans who took risperidone (110). One of the major reasons for the substantial differences in drug metabolism capacities between African black and Caucasian populations is the frequency of *CYP450* alleles, such as *CYP2D6*1* and *CYP2D6*4*. This suggests the need for a highly comprehensive pharmacogenomic testing platform (111). Based on the evidence presented, genetic testing may improve treatment effectiveness and safety for African patients with mental disorders (46).While we recognize the importance of thoroughly evaluating different approaches to candidate gene selection and considering the merits of quantitative versus categorical phenotypes, it is essential to note that the reliability and validity of the findings presented in these studies may vary.

However, the studies on the application of pharmacogenomics-guided therapy in African psychiatric practice are insufficient, and there is a lack of standardized methods for conducting pharmacogenomic tests in African countries. This situation raises questions about the feasibility of applying pharmacogenomics-guided therapy in those countries. (32). African populations could benefit from the use of pharmacogenomic testing for monitoring psychiatric medication efficacy and safety, as has been shown in other populations. However, there are still gaps in the evidence base for psychiatric pharmacogenomics in African

populations, as many candidate genes have proven difficult to replicate in the era of GWAS (112, 113). Additionally, polygenic risk scores still have limited utility due to the considerable overlap between cases and controls, resulting in low discriminative ability in the general population (114). Therefore, addressing these gaps through further research is essential, particularly in sub-Saharan countries where the burden of mental illness is high.

Challenges and opportunities for pharmacogenomics in Africa

This review has revealed that the field of pharmacogenomics research and PGx in Africa is still in its early stages and is likely to encounter several challenges during its implementation (115). Firstly, there are various obstacles in carrying out pharmacogenomic studies, such as insufficient financial support for research, inadequate infrastructure, and a shortage of trained staff, laboratories, and equipment to perform the tests (116). The limited funding available for pharmacogenomics research in Africa, coupled with the reluctance of funding organizations to invest due to concerns regarding infrastructure and trained personnel, as well as the perceived complexity of genetic research in Africa, could lead to a vicious cycle where insufficient funding hampers the development of necessary infrastructure and expertise, thereby making it difficult to attract further funding.

Notwithstanding these challenges, there are a few efforts underway to increase funding for pharmacogenomics research in Africa. For example, international organizations such as the NIH, Wellcome Trust and the EU have a strong interest to provide short term funding and other resources to support research in low- and middle-income countries, including in Africa (117). These challenges constrain our ability to increase the diversity of global pharmacogenomic databases, which presently rely on data from European or Asian populations and may not accurately predict the characteristics of patients from African populations. Consequently, the translation of existing pharmacogenomics knowledge to African populations may be limited, and the world may miss out on the potential benefits of utilizing the rare genomic diversity that exist only in African samples. Secondly, the lack of awareness among healthcare professionals, policymakers, and the public presents a significant challenge to pharmacogenomics research in Africa. Without understanding the potential benefits of pharmacogenomics, research funding can be limited, clinical translation can become more difficult, and public participation can be challenging, making it difficult to collect necessary genetic data. To address these challenges, efforts should be made to increase awareness through training programs, educational campaigns, and community

outreach initiatives. It is also crucial to involve African researchers and clinicians in the development and implementation of pharmacogenomics initiatives to ensure that they are culturally appropriate and effective (118-121). Thirdly, research ethics can be complex, and the research process may take longer than expected as it requires consideration of the diverse cultural and religious beliefs of the people and ensuring that the research is conducted with respect and ethical principles. One way to easily achieve this is by involving local communities, which can help to ensure that the research is culturally appropriate, addresses community needs and concerns, and respects local values and beliefs (122). Additionally, engaging with the community can establish trust, promoting the responsible development and implementation of the research (123).

Moreover, integration of electronic health record (HER) and longitudinal cohort allows taking advantage of already collected information to increase sample size to study uncommon exposure, rare treatment outcomes, and carry out standardized analyses. These longitudinal cohorts enable the collection of comprehensive and longitudinal data on individuals' genetic profiles, drug response, and clinical outcomes over an extended period (124). By incorporating diverse African populations into such cohorts, researchers can gain valuable insights into the genetic variations that impact drug metabolism and response (125). This information can guide the development of personalized treatment approaches and enhance medication safety and efficacy. Additionally, longitudinal cohorts provide a platform for studying the influence of environmental factors, socio-economic determinants, and lifestyle choices on drug response (126). This holistic understanding of individual and population-level factors can inform precision medicine initiatives tailored to the unique African genomic landscape. On top of this, longitudinal cohorts facilitate the assessment of long-term medication effects and the identification of rare or delayed adverse drug reactions specific to African populations (127). By leveraging the power of longitudinal cohorts, Africa can advance its capacity for PGx research, inform clinical decision-making, and ultimately improve patient outcomes in the field of precision medicine.

Despite the challenges, there are also opportunities to advance pharmacogenomic research in Africa, particularly given the growing global interest in investing in genomic diversity. National governments and international partners are showing a strong commitment to support genomic research in developing countries, including Africa. By leveraging existing platforms and building on their successes and lessons learned, initiatives such as the African Pharmacogenetics Consortium (APC) (128), the Human Heredity and Health in Africa

(H3Africa) (129) and Collaborative African Genomics Network (CAfGEN) (130) have the potential to accelerate pharmacogenomic research and implementation in Africa. The partnerships between academic institutions, research organizations, and governments in Africa are encouraging as they are actively working towards building research infrastructure and expertise, establishing data sharing mechanisms, and setting up ethical review standards across countries (130, 131). This concerted effort is facilitating the advancement of research and some African governments have recognized the importance of pharmacogenomics and are investing in research infrastructure and training programs to support research (132, 133). Pharmaceutical companies and biotechnology firms are also investing in Africa, focusing on repurposing existing drugs and developing new medications for prevalent diseases in the region (134, 135). International collaborations between African and non-African research institutions are also on the rise; they contribute funding, expertise, and provide resources that are not be available locally, which can accelerate the pace of pharmacogenomic research in Africa (134).

Strengths and limitations

One strength of our systematic review is that it provides valuable recommendations for global consortia initiatives to expand access to next-generation sequencing facilities in the region, which can increase the representation of African populations in pharmacogenomic research and enhance our understanding of the genetic factors underlying patients' response to pharmacological therapy.

However, a potential limitation of our review is that the number of studies on pharmacogenetics and pharmacogenomics of psychiatric disorders in African populations may be limited, which could impact the generalizability of our findings.

Conclusions

In summary, this review highlights the significant pharmacogenomic diversity observed in individuals of African ancestry. While the number of studies is limited, existing evidence shows variability in the frequency, distribution, and type of genetic variants within drug-metabolizing enzymes and other candidate genes involved in drug response in Africa. For example, *CYP2D6, CYP2C19, CYP3A4, CYP2B6, CYP2,* and *CYP1A2* vary widely across different African populations. Much of the current pharmacogenomics knowledge in psychiatry is based on small-scale studies, emphasizing the need for increased funding and

research infrastructure to enable the implementation of pharmacogenomic testing in psychiatric treatment. To increase the representation of African populations in pharmacogenomic research and enhance our understanding of the genetic factors underlying patients' response to pharmacological therapy, global consortia initiatives should expand access to next-generation sequencing facilities in the region. In conclusion, further research into psychiatric pharmacogenomics and pharmacogenomic diversity has the potential to revolutionize scientific knowledge, but it requires a collaborative effort to close the knowledge gap and overcome implementation barriers.

Disclosure of interest

Acknowledgment

Funding

ATA is supported by the 2019–2022 National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behaviour Research Foundation (BBRF) and National Health and Medical Research Council (NHMRC) Emerging Leadership Investigator Grant 2021 – 2008000.

References

1. Collaborators GBDMD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-50.
2. Jorns-Presentati A, Napp AK, Dessauvagie AS, Stein DJ, Jonker D, Breet E, et al. The prevalence of mental health problems in sub-Saharan adolescents: A systematic review. PLoS One. 2021;16(5):e0251689.
3. Greene MC, Yangchen T, Lehner T, Sullivan PF, Pato CN, McIntosh A, et al. The epidemiology of psychiatric disorders in Africa: a scoping review. Lancet Psychiatry. 2021;8(8):717-31.
4. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiat. 2001;62(11):869-77.
5. Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20-9.
6. Investigators G, Investigators M, Investigators SD. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170(2):207-17.
7. Pardinas AF, Nalmpanti M, Pocklington AJ, Legge SE, Medway C, King A, et al. Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism. Am J Psychiatry. 2019;176(6):477-86.
8. Quilty LC, De Fruyt F, Rolland JP, Kennedy SH, Rouillon PF, Bagby RM. Dimensional personality traits and treatment outcome in patients with major depressive disorder. J Affect Disord. 2008;108(3):241-50.
9. Bulmash E, Harkness KL, Stewart JG, Bagby RM. Personality, stressful life events, and treatment response in major depression. J Consult Clin Psychol. 2009;77(6):1067-77.
10. International Consortium on Lithium G, Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2018;75(1):65-74.
11. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, et al. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Mol Psychiatry. 2021;26(6):2457-70.
12. Amare AT, Thalamuthu A, Schubert KO, Fullerton JM, Ahmed M, Hartmann S, et al. Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder. Molecular Psychiatry. 2023.
13. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Callegari-Jacques SM, Gesteira A, et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics. 2008;18(7):599-609.
14. Cearns M, Amare AT, Schubert KO, Thalamuthu A, Frank J, Streit F, et al. Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. Br J Psychiatry. 2022:1-10.
15. Fabbri C. Genetics in psychiatry: Methods, clinical applications and future perspectives. Psychiatry and Clinical Neurosciences Reports. 2022;1(2).
16. Rayner C, Coleman JRI, Purves KL, Cheesman R, Hubel C, Gaspar H, et al. Genetic influences on treatment-seeking for common mental health problems in the UK biobank. Behav Res Ther. 2019;121:103413.
17. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-34.

18. Jukic MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry. 2018;175(5):463-70.
19. Carrascal-Laso L, Isidoro-Garcia M, Ramos-Gallego I, Franco-Martin MA. Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders. J Clin Med. 2021;10(18).
20. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011;19(3):109-24.
21. Rajman I, Knapp L, Morgan T, Masimirembwa C. African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine. 2017;17:67-74.
22. Martin AR, Teferra S, Moller M, Hoal EG, Daly MJ. The critical needs and challenges for genetic architecture studies in Africa. Curr Opin Genet Dev. 2018;53:113-20.
23. van der Doef TF, Zaragoza Domingo S, Jacobs GE, Drevets WC, Marston HM, Nathan PJ, et al. New approaches in psychiatric drug development. Eur Neuropsychopharmacol. 2018;28(9):983-93.
24. Kaosombatwattana U, Pongprasobchai S, Limsrivilai J, Maneerattanaporn M, Leelakusolvong S, Tanwandee T. Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2018;33(2):411-7.
25. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-91.
26. Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15(2):139-50.
27. Omotoso OE, Teibo JO, Atiba FA, Oladimeji T, Adebesin AO, Babalghith AO. Bridging the genomic data gap in Africa: implications for global disease burdens. Global Health. 2022;18(1):103.
28. Matimba A, Dhoro M, Dandara C. Is there a role of pharmacogenomics in Africa. Glob Health Epidemiol Genom. 2016;1:e9.
29. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
30. Amal Al O, Murry DJ. Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance. Journal of Pharmacy Practice. 2016;20(3):206-18.
31. Ammar H, Chadli Z, Mhalla A, Khouadja S, Hannachi I, Alshaikheid M, et al. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. The pharmacogenomics journal. 2021;21(5):551-8.
32. Radouani F, Zass L, Hamdi Y, Rocha JD, Sallam R, Abdelhak S, et al. A review of clinical pharmacogenetics Studies in African populations. Per Med. 2020;17(2):155-70.
33. Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry. 2008;63(1):32-41.
34. Drogemoller BI, Wright GEB, Warnich L. Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opin Drug Metab Toxicol. 2014;10(6):873-84.
35. Drogemoller BI, Niehaus DJ, Chiliza B, van der Merwe L, Asmal L, Malhotra AK, et al. Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics. 2014;15(2):189-99.
36. Drogemoller BI, Emsley R, Chiliza B, Van Der Merwe L, Wright GEB, Daya M, et al. The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. Pharmacogenet Genomics. 2016;26(5):235-42.
37. O'Connell KS, McGregor NW, Emsley R, Seedat S, Warnich L. The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients. Front Genet. 2019;10:9.

38. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. The pharmacogenomics journal. 2009;9(5):311-8.
39. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;20(5):555-62.
40. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry. 2008;165(4):497-506.
41. Wonodi I, Mitchell BD, Stine OC, Hong LE, Elliott A, Kirkpatrick B, et al. Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct. 2006;2:42.
42. Benmessaoud D, Hamdani N, Boni C, Ramoz N, Hamon M, Kacha F, et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC psychiatry. 2008;8:40.
43. Ovenden ES, Drogemoller BI, van der Merwe L, Chiliza B, Asmal L, Emsley RA, et al. Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms. Pharmacogenomics. 2017;18(2):105-20.
44. Liou YJ, Wang HH, Lee MT, Wang SC, Chiang HL, Chen CC, et al. Genome-wide association study of treatment refractory schizophrenia in Han Chinese. PLoS One. 2012;7(3):e33598.
45. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl). 2005;181(1):179-87.
46. Dodgen TM, Eloff A, Mataboge C, Roos LJ, van Staden WC, Pepper MS. Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. Appl Transl Genom. 2015;5:40-6.
47. Pardinas AF, Kappel DB, Roberts M, Tipple F, Shitomi-Jones LM, King A, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry. 2023;10(3):209-19.
48. Motta I, Calcagno A, Baietto L, D'Avolio A, de Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19. Infez Med. 2015;23(4):367-9.
49. Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Archives of general psychiatry. 2010;67(4):369-79.
50. Murphy E, Hou L, Maher BS, Woldehawariat G, Kassem L, Akula N, et al. Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacology. 2013;38(13):2598-606.
51. Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, et al. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics. 2017;18(5):433-43.
52. Kirchheiner J, Keulen JTHA, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol. 2008;28(1):78-83.
53. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17(2):93-101.
54. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. British journal of clinical pharmacology. 1999;48(3):395-401.

55. Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Annals of human genetics. 2010;74(4):340-50.
56. Masimirembwa CM, Beke M, Hasler JA, Tang BK, Kalow W. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther. 1995;57(1):25-31.
57. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics. 1993;3(6):275-80.
58. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59(1):5-12.
59. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, De Sommers K, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57(1):11-7.
60. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics. 1996;6(6):521-6.
61. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-13.
62. Miura J, Obua C, Abbo C, Kaneko S, Tateishi T. Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol. 2009;65(3):319-20.
63. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther. 1995;57(6):656-61.
64. Nsabiyumva F, Furet Y, Autret E, Jonville AP, Breteau M. Oxidative polymorphism of dextromethorphan in a Burundi population. Eur J Clin Pharmacol. 1991;41(1):75-7.
65. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093-108.
66. Mouterde M, Daali Y, Rollason V, Cizkova M, Mulugeta A, Al Balushi KA, et al. Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans. Genome Biol Evol. 2022;14(12):23.
67. Motshoge T, Tawe L, Muthoga CW, Allotey J, Romano R, Quaye I, et al. Cytochrome P450 2C8*2 allele in Botswana: Human genetic diversity and public health implications. Acta tropica. 2016;157:54-8.
68. Bayoumi RAL, Qureshi MM, Al-Ameri MM, Woolhouse NM. The N-acetyltransferase G191 a mutation among Sudanese and Somalis. Pharmacogenetics. 1997;7(5):397-9.
69. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285-306.
70. Ali AA, Aalto M, Jonasson J, Osman A. Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population. Scientific reports. 2020;10(1):5652.
71. Merwe NVD, Bouwens CSH, Pienaar R, Merwe LVD, Yako YY, Geiger DH, et al. CYP2D6 genotyping and use of antidepressants in breast cancer patients: Test development for clinical application. Metab Brain Dis. 2012;27(3):319-26.
72. Dodgen TM, Eloff A, Mataboge C, Roos L, van Staden W, Pepper MS. Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. Appl Transl Genomics. 2015;5:40-6.
73. Ajmi M, Boujaafar S, Zouari N, Amor D, Nasr A, Rejeb NB, et al. Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population. The International journal of neuroscience. 2018;128(8):705-14.

74. Afilal D, Basselam MA, Brakez Z, Chouham S, Brehm A, Izaabel EH. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. Genetic testing and molecular biomarkers. 2017;21(5):298-304.
75. Adehin A, Bolaji OO, Maggo S, Kennedy MA. Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population. Drug metabolism and personalized therapy. 2017;32(1):39-47.
76. Adehin A, Bolaji OO, Kennedy MA. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Drug metabolism and pharmacokinetics. 2017;32(3):189-91.
77. Santovito A, Burgarello C, Cervella P, Delpero M. Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast). Genet Mol Biol. 2010;33(3):434-7.
78. Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol. 2005;60(12):855-7.
79. Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJJ. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. British journal of clinical pharmacology. 1999;48(3):402-8.
80. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics. 1999;9(6):715-23.
81. Horsmans Y, Kanyinda JM, Desager JP. Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects. PHARMACOL TOXICOL. 1996;78(2):86-8.
82. Gomez F, Hirbo J, Tishkoff SA. Genetic variation and adaptation in Africa: implications for human evolution and disease. Cold Spring Harb Perspect Biol. 2014;6(7):a008524.
83. Mathuba B, Koromina M, Mitropoulou C, Patrinos GP. Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa. Pharmacogenomics. 2021;22(2):115-22.
84. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010;35(6):1315-24.
85. Bentley AR, Callier SL, Rotimi CN. Evaluating the promise of inclusion of African ancestry populations in genomics. NPJ Genom Med. 2020;5:5.
86. Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res. 2013;149(1-3):1-14.
87. Cacabelos R, Martinez-Bouza R. Genomics and pharmacogenomics of schizophrenia. CNS Neurosci Ther. 2011;17(5):541-65.
88. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16(5):481-5.
89. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2012;12(2):165-72.
90. Lo C, Nguyen S, Yang C, Witt L, Wen A, Liao TV, et al. Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. Clin Transl Sci. 2020;13(5):861-70.
91. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39(4):121-7.
92. Liu J, Cui JY, Lu YF, Corton JC, Klaassen CD. Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers. Drug Metab Dispos. 2021;49(1):111-9.
93. Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6):e00890.

94. Pennazio F, Brasso C, Villari V, Rocca P. Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review. Pharmaceutics. 2022;14(12).
95. Strawn JR, Poweleit EA, Uppugunduri CRS, Ramsey LB. Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors. Front Pharmacol. 2021;12:749692.
96. Law S, Gudbrandsen M, Magill N, Sweetman I, Rose D, Landau S, et al. Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study. J Psychopharmacol. 2015;29(8):933-42.
97. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008;9:403-33.
98. Adeyemo AA, Chen G, Chen Y, Rotimi C. Genetic structure in four West African population groups. BMC Genet. 2005;6:38.
99. Bochud M, Guessous I. Gene-environment interactions of selected pharmacogenes in arterial hypertension. Expert Rev Clin Pharmacol. 2012;5(6):677-86.
100. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59-67.
101. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461-5.
102. Mpye KL, Matimba A, Dzobo K, Chirikure S, Wonkam A, Dandara C. Disease burden and the role of pharmacogenomics in African populations. Glob Health Epidemiol Genom. 2017;2:e1.
103. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23(10):535-48.
104. da Rocha JEB, Othman H, Botha G, Cottino L, Twesigomwe D, Ahmed S, et al. The Extent and Impact of Variation in ADME Genes in Sub-Saharan African Populations. Front Pharmacol. 2021;12:634016.
105. Mukonzo JK. The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa. AIDS. 2014;28(13):1855-7.
106. Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol. 2014;10(6):769-85.
107. Awandu SS, Raman J, Makhanthisa TI, Kruger P, Frean J, Bousema T, et al. Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa. Malar J. 2018;17(1):120.
108. Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. The pharmacogenomics journal. 2017;17(1):61-8.
109. Goulding R, Dawes D, Price M, Wilkie S, Dawes M. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. British journal of clinical pharmacology. 2015;80(4):868-77.
110. Shad MU. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside. Behav Sci (Basel). 2021;11(7).
111. Franco-Martin MA, Sans F, Garcia-Berrocal B, Blanco C, Llanes-Alvarez C, Isidoro-Garcia M. Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report. Clin Psychopharmacol Neurosci. 2018;16(3):349-57.
112. Marigorta UM, Rodriguez JA, Gibson G, Navarro A. Replicability and Prediction: Lessons and Challenges from GWAS. Trends Genet. 2018;34(7):504-17.
113. Ertekin-Taner N. Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther. 2010;2(1):3.

114. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44.
115. Adiukwu F, Essien EA, Adesokun O, Ofori S. Psychiatry pharmacogenomics: Africans are not at the table. Lancet Psychiatry. 2023;10(2):80.
116. Florence Femi Odekunle ROO, Srinivasan Shankar. Why sub-Saharan Africa lags in electronic health record adoption and possible strategies to increase its adoption in this region. International Journal of Health Sciences-Ijhs. 2017;11(4).
117. Zhong A, Darren B, Loiseau B, He LQB, Chang T, Hill J, et al. Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review. Genet Med. 2021;23(12):2270-80.
118. Karen Maigetter AMP, Abhay Kadam, Kim Ward, Mitchell G. Weiss. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. International Journal of Health Policy and Management. 2015;4(5):295-305.
119. June C. Carroll ALR, Brenda J. Wilson, Judith Allanson, Sean M. Blaine,Mary Jane Esplen, Sandra A. Farrell, Gail E. Graham, Jennifer MacKenzie, Wendy Meschino, Fiona Miller, Preeti Prakash, Cheryl Shuman, Anne Summers, Sherry Taylor. Genetic education for primary care providers:Improving attitudes, knowledge, and confidence. Canadian Family Physician. 2009;55.
120. Ogunrin O, Taiwo F, Frith L. Genomic Literacy and Awareness of Ethical Guidance for Genomic Research in Sub-Saharan Africa: How Prepared Are Biomedical Researchers? J Empir Res Hum Res Ethics. 2019;14(1):78-87.
121. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet. 2001;4(4):204-14.
122. Mahomed S. Human Biobanking in Developed and Developing Countries: An Ethico-Legal Comparative Analysis of the Frameworks in the United Kingdom, Australia, Uganda, and South Africa. Camb Q Healthc Ethics. 2021;30(1):146-60.
123. Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 2009;12(3):131-3.
124. Rodriguez-Laso A, Rico-Uribe LA, Kubiak C, Haro JM, Rodriguez-Manas L, Ayuso JL. A Map of the Initiatives That Harmonize Patient Cohorts Across the World. Front Public Health. 2021;9:666844.
125. Gomez-Olive FX, Montana L, Wagner RG, Kabudula CW, Rohr JK, Kahn K, et al. Cohort Profile: Health and Ageing in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI). Int J Epidemiol. 2018;47(3):689-90j.
126. Suissa S, Moodie EEM, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiology and Drug Safety. 2017;26(4):459-68.
127. Mekonnen AB, Alhawassi TM, McLachlan AJ, Brien J-aE. Adverse Drug Events and Medication Errors in African Hospitals: A Systematic Review. Drugs - Real World Outcomes. 2017;5(1):1-24.
128. Dandara C, Masimirembwa C, Haffani YZ, Ogutu B, Mabuka J, Aklillu E, et al. African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. AAS Open Res. 2019;2:19.
129. Human Heredity & Health in Africa (H3Africa) [Internet]. 2020 [cited March 24, 2023]. Available from: https://h3africa.org/.
130. Mboowa G, Mwesigwa S, Katagirya E, Retshabile G, Mlotshwa BC, Williams L, et al. The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa. AAS Open Res. 2018;1:3.
131. Obamba MO, Mwema JK. Symmetry and Asymmetry: New Contours, Paradigms, and Politics in African Academic Partnerships. Higher Education Policy. 2009;22(3):349-71.

132. Munung NS, Mayosi BM, de Vries J. Equity in international health research collaborations in Africa: Perceptions and expectations of African researchers. PLoS One. 2017;12(10):e0186237.
133. Chowdhury A, Fakruddin M. Pharmacogenomics- The Promise of Personalized Medicine. Bangladesh Journal of Medical Science. 2013;12(4):346-56.
134. Zycher B, DiMasi JA, Milne CP. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Am J Ther. 2010;17(1):101-20.
135. Sharawy I. Ethical and Regulatory Issues in Genetic Research Collaboration between Global Pharmaceutical Industry and Low- and Middle-income Countries. Research Square. 2022.